Crohn's Disease

A recent study showed that dual biologic therapy was linked to clinical and endoscopic improvements among patients with refractory Crohn’s disease. It was the top story in gastroenterology last week.

Patients who underwent vagotomy were at greater risk for later development of inflammatory bowel disease, indicating the beneficial role of the vagal tone in IBD, according to research published in Alimentary Pharmacology & Therapeutics.

Treatment with dual biologic therapy was associated with clinical and endoscopic improvements in patients with Crohn’s disease who previously failed multiple biologics, according to study results.

Identifying which patients respond quickly to dietary therapies for Crohn’s disease may help indicate which ones will succeed long term and which ones might do better on a different therapy, according to study results.

The American Gastroenterological Association issued new guidance for the clinical management of patients with inflammatory bowel disease during the COVID-19 pandemic.

In this exclusive video series, Stephen B. Hanauer, MD, medical director of the Digestive Health Center at Northwestern University Feinberg School of Medicine, discusses the impact of COVID-19 on the world of gastroenterology. In this video, he told Healio Gastroenterology and Liver Disease about how it has affected patients with inflammatory bowel disease, as well as clinical trials.

Early biologic treatment is associated with improved outcomes in patients with Crohn’s disease, according to study results.

A panel of serum antibodies and proteins helped identify patients who later received a diagnosis of Crohn’s disease within 5 years, according to research published in Gastroenterology.

For some patients with inflammatory bowel disease, treatments can be ineffective, and in patients where they do work, they do not always last.

Inflammatory bowel disease is a debilitating condition that takes a lifetime of treatment to control. Over the years, medical therapies for the disease have evolved greatly, but the approval of anti-tumor necrosis factor alpha therapy for the treatment of Crohn’s disease in 1998 was a turning point in IBD treatment management.